{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:59Z","timestamp":1793330819994,"version":"4.5.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"\n Importance<\/jats:title>\n The 2026 American Heart Association\/American College of Cardiology\/multisociety guideline on the management of dyslipidemia issued new recommendations on estimating atherosclerotic cardiovascular disease (ASCVD) risk and on populations eligible for statins for primary prevention.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the population health impact of the 2026 guideline on primary prevention statin therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Nationally representative, cross-sectional sample of nonpregnant adults aged 30 to 79 years without known ASCVD, who participated in the National Health and Nutrition Examination Survey from 2017 to 2023. Data were analyzed from March to May 2026.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Changes in eligibility for primary prevention statin therapy, comparing the 2026 and 2018 lipid guidelines.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The weighted sample included 4366 NHANES participants representative of 154.5 million US adults (weighted mean age, 51 years; 52.0% female). Of these, 5.5% (95% CI, 4.7%-6.6%) had untreated low-density lipoprotein cholesterol below 70 mg\/dL, 17.8% (95% CI, 16.3%-19.5%) reported currently taking statins, and 8.6% (95% CI, 7.6%-9.8%) met criteria for statin eligibility independent of ASCVD risk estimation based on a low-density lipoprotein cholesterol of 190 mg\/dL or greater, diabetes, or chronic kidney disease. The remaining 68.0% of patients (95% CI, 65.9%-70.0%) met guideline criteria for using ASCVD risk estimation to guide statin decisions. In total, an estimated 87.5 million (56.6% [95% CI, 54.2%-58.9%]) nonpregnant US adults aged 30 to 79 years were statin eligible based on the 2026 guideline, including 21.5 million (13.9% [95% CI, 12.5%-15.5%]) who were newly statin eligible. More than 93% of adults aged 70 to 79 years and 85% of adults aged 60 to 69 years are eligible for primary prevention statin therapy compared with 11% of adults aged 30 to 39 years. Newly statin-eligible populations were largely younger and lower risk than populations previously recommended statin therapy (mean estimated 10-year ASCVD risk, 3.1% [95% CI, 2.7%-3.5%] for newly statin-eligible individuals vs 6.1% [95% CI, 5.8%-6.4%] for individuals previously eligible for statin therapy).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly in lower-risk individuals.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.11246","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:30:25Z","timestamp":1784561425000},"page":"557","source":"Crossref","is-referenced-by-count":4,"title":["Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy"],"prefix":"10.1001","volume":"336","author":[{"given":"Timothy S.","family":"Anderson","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Center for Healthcare Evaluation, Research, and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Sussman","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"joi260074r1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2022.12567","article-title":"Trends in lipid concentrations and lipid control among US adults, 2007-2018.","volume":"328","author":"Aggarwal","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"joi260074r2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.7326\/M23-1915","article-title":"Trends in primary prevention statin use by cardiovascular risk score from 1999 to 2018: a repeated cross-sectional study.","volume":"176","author":"Kim","year":"2023","journal-title":"Ann Intern Med"},{"issue":"5","key":"joi260074r3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamacardio.2023.0228","article-title":"Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.","volume":"8","author":"Jacobs","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"19","key":"joi260074r4","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"joi260074r5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations.","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"joi260074r7","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"joi260074r8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","article-title":"Atherosclerotic cardiovascular disease risk estimates using the Predicting Risk of Cardiovascular Disease Events equations.","volume":"184","author":"Anderson","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"12","key":"joi260074r9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jama.2024.12537","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations.","volume":"332","author":"Diao","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"joi260074r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.125.012348","article-title":"Thirty-year atherosclerotic cardiovascular disease risk among US adults aged 30 to 59 years.","volume":"19","author":"Anderson","year":"2026","journal-title":"Circ Popul Health Outcomes"},{"issue":"19","key":"joi260074r11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"joi260074r12","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"joi260074r13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/2047487313483600","article-title":"Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"joi260074r14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk.","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"joi260074r15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-026-10423-5","article-title":"Prevalence of atherosclerotic cardiovascular disease risk-enhancing factors and their association with primary prevention statin use.","author":"Wilson","year":"2026","journal-title":"J Gen Intern Med"},{"issue":"2","key":"joi260074r16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease.","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"joi260074r6","unstructured":"US Centers for Disease Control and Prevention. About NHANES. December 18, 2024. Accessed March 18, 2026. https:\/\/www.cdc.gov\/nchs\/nhanes\/about\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2851792\/jama_anderson_2026_oi_260074_1786039302.22352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:09:31Z","timestamp":1787065771000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2851792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.11246","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}